332 related articles for article (PubMed ID: 35459184)
41. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
42. Ferulic acid reverses P-glycoprotein-mediated multidrug resistance via inhibition of PI3K/Akt/NF-κB signaling pathway.
Muthusamy G; Gunaseelan S; Prasad NR
J Nutr Biochem; 2019 Jan; 63():62-71. PubMed ID: 30342318
[TBL] [Abstract][Full Text] [Related]
43. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
Mi YJ; Liang YJ; Huang HB; Zhao HY; Wu CP; Wang F; Tao LY; Zhang CZ; Dai CL; Tiwari AK; Ma XX; To KK; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2010 Oct; 70(20):7981-91. PubMed ID: 20876799
[TBL] [Abstract][Full Text] [Related]
44. Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells.
Zhang DM; Li YJ; Shu C; Ruan ZX; Chen WM; Yiu A; Peng YH; Wang J; Lan P; Yao Z; Fung KP; Fu LW; Chen ZS; Ye WC
Anticancer Drugs; 2013 Jun; 24(5):441-54. PubMed ID: 23466650
[TBL] [Abstract][Full Text] [Related]
45. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
46. DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway.
Qiu L; Ma Z; Li X; Deng Y; Duan G; Zhao LE; Xu X; Xiao L; Liu H; Zhu Z; Chen H
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1202-1214. PubMed ID: 33079995
[TBL] [Abstract][Full Text] [Related]
47. Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells.
Cui Q; Cai CY; Wang JQ; Zhang S; Gupta P; Ji N; Yang Y; Dong X; Yang DH; Chen ZS
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443367
[TBL] [Abstract][Full Text] [Related]
48. Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.
Wu ZX; Teng QX; Cai CY; Wang JQ; Lei ZN; Yang Y; Fan YF; Zhang JY; Li J; Chen ZS
Biochem Pharmacol; 2019 Aug; 166():120-127. PubMed ID: 31078601
[TBL] [Abstract][Full Text] [Related]
49. Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.
Wang SQ; Liu ST; Zhao BX; Yang FH; Wang YT; Liang QY; Sun YB; Liu Y; Song ZH; Cai Y; Li GF
Oncotarget; 2015 Sep; 6(28):26142-60. PubMed ID: 26317651
[TBL] [Abstract][Full Text] [Related]
50. Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer.
Yuan ZT; Shi XJ; Yuan YX; Qiu YY; Zou Y; Liu C; Yu H; He X; Xu K; Yin PH
Oncotarget; 2017 Jul; 8(29):48012-48026. PubMed ID: 28624793
[TBL] [Abstract][Full Text] [Related]
51. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
52. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
53. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).
Heffeter P; Jakupec MA; Körner W; Chiba P; Pirker C; Dornetshuber R; Elbling L; Sutterlüty H; Micksche M; Keppler BK; Berger W
Biochem Pharmacol; 2007 Jun; 73(12):1873-86. PubMed ID: 17445775
[TBL] [Abstract][Full Text] [Related]
54. Development of Polymersomes Co-Delivering Doxorubicin and Melittin to Overcome Multidrug Resistance.
Han E; Kim D; Cho Y; Lee S; Kim J; Kim H
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770754
[TBL] [Abstract][Full Text] [Related]
55. Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Li W; Zhai B; Zhi H; Li Y; Jia L; Ding C; Zhang B; You W
Tumour Biol; 2014 Sep; 35(9):8883-91. PubMed ID: 24894670
[TBL] [Abstract][Full Text] [Related]
56. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
[TBL] [Abstract][Full Text] [Related]
57. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
58. The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Duran GE; Sikic BI
PLoS One; 2019; 14(1):e0210879. PubMed ID: 30668583
[TBL] [Abstract][Full Text] [Related]
59. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells.
Hui RC; Francis RE; Guest SK; Costa JR; Gomes AR; Myatt SS; Brosens JJ; Lam EW
Mol Cancer Ther; 2008 Mar; 7(3):670-8. PubMed ID: 18347152
[TBL] [Abstract][Full Text] [Related]
60. miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells.
Shi X; Valizadeh A; Mir SM; Asemi Z; Karimian A; Majidina M; Safa A; Yosefi B
Eur J Pharmacol; 2020 Aug; 880():173138. PubMed ID: 32416187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
